ArticleChemistry & biology2008
Covalent and noncovalent intermediates of an NAD utilizing enzyme, human CD38.
Article in Chemistry & biology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 43 citations in OpenAlex.
- Emerging chemical strategies for CD38 inhibition: restoring NADBioorganic & medicinal chemistry · 2026Review
- Modulating CD38 enzymatic activity during antibody-based immunotherapy in multiple myeloma: a basic science perspective.Frontiers in immunology · 2026Article
- Targeting prostate cancer with site-specific antibody-drug conjugates enabled by tandemly fused ADP-ribosyl cyclases.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2025Article
- The role of NADnpj metabolic health and disease · 2025Review
- Article
- SARM1, an Enzyme Involved in Axon Degeneration, Catalyzes Multiple Activities through a Ternary Complex Mechanism.Biochemistry · 2023Article
- The chemical biology of NADCurrent opinion in chemical biology · 2022Review
- Synthesis of site-specific antibody-drug conjugates by ADP-ribosyl cyclases.Science advances · 2020Article
- A Cell-Permeant Mimetic of NMN Activates SARM1 to Produce Cyclic ADP-Ribose and Induce Non-apoptotic Cell Death.iScience · 2019Article
- The choice of sequence homologs included in multiple sequence alignments has a dramatic impact on evolutionary conservation analysis.Bioinformatics (Oxford, England) · 2019Article
- Porcine CD38 exhibits prominent secondary NAD(+) cyclase activity.Protein science : a publication of the Protein Society · 2016Article
- Design, synthesis and SAR studies of NAD analogues as potent inhibitors towards CD38 NADase.Molecules (Basel, Switzerland) · 2014Article
- Identification of ADP-ribosylation sites of CD38 mutants by precursor ion scanning mass spectrometry.Analytical biochemistry · 2013Article
- Cyclic ADP-ribose and nicotinic acid adenine dinucleotide phosphate (NAADP) as messengers for calcium mobilization.The Journal of biological chemistry · 2012Review
- The ΔC splice-variant of TRPM2 is the hypertonicity-induced cation channel in HeLa cells, and the ecto-enzyme CD38 mediates its activation.The Journal of physiology · 2012Article
- Article
- Design, synthesis and biological characterization of novel inhibitors of CD38.Organic & biomolecular chemistry · 2011Article
- Dynamic conformations of the CD38-mediated NAD cyclization captured in a single crystal.Journal of molecular biology · 2011Article
- Sirtuin chemical mechanisms.Biochimica et biophysica acta · 2010Review
- Glycal formation in crystals of uridine phosphorylase.Biochemistry · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
Abstract
Enzymatic utilization of nicotinamide adenine dinucleotide (NAD) has increasingly been shown to have fundamental roles in gene regulation, signal transduction, and protein modification. Many of the processes require the cleavage of the nicotinamide moiety from the substrate and the formation of a reactive intermediate. Using X-ray crystallography, we show that human CD38, an NAD-utilizing enzyme, is capable of catalyzing the cleavage reactions through both covalent and noncovalent intermediates, depending on the substrate used. The covalent intermediate is resistant to further attack by nucleophiles, resulting in mechanism-based enzyme inactivation. The noncovalent intermediate is stabilized mainly through H-bond interactions, but appears to remain reactive. Our structural results favor the proposal of a noncovalent intermediate during normal enzymatic utilization of NAD by human CD38 and provide structural insights into the design of covalent and noncovalent inhibitors targeting NAD-utilization pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.